Table 3.
Polymer- and dendrimer-based miRNAs delivery and their therapeutic effects
| Cell lines | Loaded therapeutic agent | Polymer type/name | Biological effect | Molecular changes | Model of study | References |
|---|---|---|---|---|---|---|
| GBM1A or GBM1B | miR-148a and miR-296-5 | Bioreducible poly(β-amino ester) nanoparticles (R646 nano-miRs) | Reduced the stem-like characteristics | Down-regulation of SOC2, NANOG, BMI, OLIG2 | In vitro: human GBM cells and orthotopic In vivo: human GBM xenografts | [79] |
| MDA-MB-231 | antagomiR-221, miR-205 mimic | RNA-triple-helix hydrogel nanoconjugates | Decreased invasion and tumorigenicity, smaller tumor size, no systemic toxicity | NA | In vivo: orthotopic TNBC mouse model | [94] |
| U251 | miR-7 | poly(amido amine) (FA/PAMAM/miR-7) | Decreased proliferation and invasion, increased apoptosis, smaller tumor size | Down-regulation of EGFR, PI3 K, AKT2 |
In vitro: human glioma cells In vivo: brain-glioma mouse model |
[95] |
| A549 | miR-34a | S6 aptamer-conjugated dendrimer (PAM-Ap/pMiR-34a) | Decreased viability, increased apoptosis, migration, invasion | Up-regulation of p53, BCL-2 (only mRNA) | In vitro: human NSCLC cells | [100] |
| Huh7 | antimiR122 PNA | Porous silicon nanoparticles (PSNPs)—polymer nanocomposites | Improved bioavailability | NA |
In vitro: Human hepatocellular carcinoma cells In vivo: C57BL/6 J mice for evaluation of liver related parameters |
[101] |
| U87MG (HTB-14) and Ln229 (CRL2611) | antagomiR-21 and antagomiR-10b | cRGD-tagged PEG-PLGA nanoparticles | Increased apoptosis, impaired cell cycle progression |
Down-regulation of PTEN (mRNA) Up-regulation of PDCD4, PTEN (protein), CASP3 l |
In vitro: human glioblastoma multiforme (GBM) cells In vivo: human GBM cell xenografts mice model |
[80] |